Henry Ford Health Study: Hydroxychloroquine Lowers the Death Rate of People Infected with COVID

In March 2020, the FDA granted emergency use authorization (EUA) for Hydroxychloroquine but they revoked the EUA for HCQ a few months later on June 15, 2020 after determining that the "legal criteria for issuing an EUA were no longer met".

In May 2020, the Henry Ford Health Institute (HFHI) concluded a study on the efficacy of HCQ to treat SARS-COV-2. The HFHI study concluded that not only was HCQ safe, but it was effective for treating SARS-COV-2 and lowering the death rate.

One of the arguments that the media made about about HCQ between when it was approved for EUA and when EUA was revoked was that HCQ was unsafe, often claiming HCQ could cause heart problems despite being FDA approved for other ailments for decades.

Under testimony in July 2020, Dr. Fauci stated he could not endorse the drug (HCQ) because their was not a randomize placebo control trial performed.